The Coderegenesis Cervical Cancer Portfolio supports clinical decision-making across the continuum of screening, triage and diagnosis.
The Coderegenesis cervical cancer portfolio provides three clinically validated tests to help identify women at risk of cervical cancer and improve detection and confirmation of high-grade disease in a single round of screening. Our portfolio of proven molecular and tissue-based tests utilizes the science of HPV and biomarker technology to deliver highly sensitive and specific results, helping bring more clarity of answers for clinical decisions.
Be confident with crb® HPV test
Screening with HPV DNA can identify women at risk for cervical cancer. crb® HPV simultaneously provides pooled results on known high-risk HPV genotypes and individual results on the two highest-risk genotypes, HPV 16 and HPV 18, giving three results in one from a single sample.
